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Abstract
The social acceptability of germline genome editing (GGE) depends on its perceived safety, as well as respect for
reproductive autonomy. However, it is doubtful that prospective parents sufficiently understand the risks of GGE.
In the future, the use of GGE in specific situations seems plausible, as it offers couples potential means to safe-
guard genetically related future children from a serious disease and overcome infertility due to a gene mutation.
Should GGE fail, however, some couples may be obliged to abort affected fetuses, or give birth to adversely af-
fected children, which would be a tragedy. Some children might develop diseases later in life due to overlooked
off-target mutations. Compounding this, some parents are unlikely to inform their offspring about the details of
conception, hampering necessary follow-up. Prospective parents, scientists and policy makers should carefully
discuss the safety implications of GGE for genetically related future children.
Introduction
In theory, genetically modifying human germ cells, which
include the egg cells, sperm cells, and zygotes (collec-
tively referred to as the germline), can enhance the devel-
opmental potential of embryos and result in children with
an intended trait. However, due to the inheritance of ge-
netic modification among future generations, germline
genetic modification has been tremendously controver-
sial, raising concerns over the safety and welfare of future
generations, potential changes to the nature of human re-
production and parent–child relationships, exacerbation
of prejudice against people with disabilities, and potential
misuse for genetic enhancement.1
In the past two decades, some clinics have attempted
to use germline genetic modifications primarily to treat
intractable infertility.2,3 Since 1996, several reproduc-
tive techniques involving cytoplasmic or nuclear trans-
fer have been developed to modify the composition of
mitochondrial genome (mtDNA) of human eggs or zy-
gotes using donor eggs.3 Although some of these cases
led to live births, others resulted in miscarriages, chro-
mosomally abnormal pregnancies, and the development
of disorders in offspring.3,4 Although some countries
have prohibited such germline genetic modification,
the United Kingdom became the first nation explicitly
to permit two types of cytoplasmic replacement using
nuclear transfer to exclude most mutated mitochondria
in the eggs or zygotes (mitochondrial donation) in 2015
in order to allow prospective parents to have geneti-
cally related children free from serious mitochondrial
disease.5
Recently, genetic modification technologies using pro-
grammable bacterial nucleases (DNA-cutting enzymes),
collectively called ‘‘genome editing,’’ have spread world-
wide as efficient, versatile, and cheap genetic engineering
tools. One of them, CRISPR-Cas9, uses nucleases and
programmable guide RNA molecules to modify specific
genes in the nuclear and mitochondrial genomes of vari-
ous species.6 Since 2015, basic research on human germ-
line genome editing (GGE) has proceeded toward clinical
applications to prevent genetic disease prenatally.7–9 In
contrast to germline genetic modifications through cyto-
plasmic or nuclear transfer, GGE technically does not de-
pend on gamete donation from third parties. It requires
only the introduction of programmed nucleases into the
germline. Therefore, it is likely that more prospective
parents will consider GGE more favorably. Indeed, a re-
cent survey found that approximately 60% of respondents
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accept GGE for medical purposes, whereas only 27% ac-
cept it for nonmedical purposes.10
Nonetheless, reports on basic research into GGE tech-
nology have still stirred a fierce global debate. In re-
cent years, international societies and communities have
issued more than 60 ethics statements regarding GGE.11
Notably, a 2017 report by the U.S. National Academies
of Sciences, Engineering, and Medicine (NASEM) con-
cluded that GGE trials might be permitted only after fur-
ther preclinical research clarifies the potential ‘‘risks and
benefits,’’ and only for ‘‘compelling medical reasons .
[in the] . absence of reasonable alternatives.’’12 Addi-
tionally, a 2018 report by the Nuffield Council on Bio-
ethics (NCB) in the United Kingdom concluded that
GGE could be acceptable if it is intended to secure, and
be consistent with, the ‘‘welfare .[ of the] . future per-
son’’ and should not increase disadvantage, discrimina-
tion, or division in society.13
At the end of 2018, a Chinese researcher, who asserted
that his research conformed with the guidelines of the
NASEM report, claimed that twin girls had been born safely
via GGE using CRISPR-Cas9.14 Subsequently, a Chinese
regional government confirmed their births but found seri-
ous compliance violations.15 In this use of CRISPR-Cas9,
the researcher attempted to introduce a CCR5 gene deletion
that confers resistance to human immunodeficiency virus
(HIV) infection (naturally found in approximately 10% of
Northern European populations). Importantly, the father of
the twins was HIV-positive, and both parents considered
that providing HIV resistance for their future children
would enhance the welfare of their offspring. However, in
this and other cases, GGE might unintentionally cause
off-target mutations in genes that are important for health,
which can potentially affect the resultant embryos, fetuses,
and children systemically, infringing on their human rights.
Therefore, we must be aware that a world where GGE
is available either legally or illicitly is imminent. Before
prospective parents with autonomy widely pursue exper-
imental GGE, it is imperative that we consider the safety
of GGE and its social implications. To facilitate much-
needed discussion, the present article will examine the
safety of GGE for medical purposes.
Differences Between Somatic Editing
and Germline Editing
Previously, in two trials of conventional somatic gene
therapy for a severe combined immunodeficiency (SCID),
5/20 subjects developed leukemia several years after
the administration of CD34+ progenitor cells in which
a retroviral vector encoding IL2RG was introduced.16,17
The side effect of leukemia was due to the activation of
protooncogenes caused by the genomic insertion of retro-
viral vectors in an unintended manner. Physicians treated
the five affected subjects, and while four recovered, one
ultimately died. However, the safety of viral vectors has
recently been improved.18 Currently, clinical trials using
somatic cell genome editing (SGE) are ongoing to develop
novel therapies for patients with cancers and genetic dis-
eases.6 In SGE, programmed nucleases are introduced
into somatic cells, and then a target DNA sequence is ef-
ficiently cut and modified for a therapeutic effect. How-
ever, there remains a risk of unintentional large-scale
rearrangements or small insertion and deletion mutations
at off-target sites,19 which could result in serious side ef-
fects, including tumor formation through the activation of
protooncogenes or disruption of tumor suppressor genes.20
Despite the different mechanisms between SGE and more
traditional gene therapy, such unintended genetic modifica-
tions are irretrievable and persistent in some cells of sub-
jects, which drastically differentiates SGE and gene
therapy from chemical agents that are soon metabolized
and excreted from the body.20 Before obtaining consent
from volunteers, the potential risks and burdens, as well
as the benefits of SGE, must be carefully explained to them.
The use of germline genetic modification in the con-
text of contemporary reproductive medicine introduces
more complex ethical issues into the debate. In this
case, the individuals providing consent will be prospec-
tive parents. However, the actual subjects being directly
affected will be eggs or sperm cells, embryos, and ulti-
mately children via reproduction. Of course, unborn chil-
dren cannot be informed of the risks and cannot give
consent. Again, we consider the case of germline genetic
modifications through cytoplasmic or nuclear transfer, in-
cluding mitochondrial donation. These processes involve
the transfer of mitochondria (containing their mitochon-
drial genome) from eggs donated from a third party, and
thus are controversial due to their involvement of a third
‘‘parent’’ in the in vitro fertilization (IVF) process.21,22
The direct use of donor eggs can help prospective par-
ents have children, but at the same time, egg donation
has raised ethical issues concerning female exploitation
and the commodification of eggs in addition to potential
harms to female donors.23 Moreover, the intended mother
is not genetically related to the donor-conceived children,
which can also lead to concerns, such as emotional con-
flict over whether to disclose the fact of donor conception
to the children,24 and problems of resemblance due to a
lack of physical similarity between the mother and such
children.25 Mitochondrial donation could alleviate these
concerns by helping prospective mothers who consent
to it to have genetically related children (genetically re-
lated children free from mitochondrial disease when the
prospective mothers have a pathogenic mtDNA).
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The fact that GGE does not technically require gam-
ete donation will make it more appealing to prospective
parents, including parents who seek genetically related
children free from disease, as well as parents wishing
to overcome infertility due to a gene mutation.26,27 How-
ever, there is no medicine without risks. In the above-
mentioned Chinese GGE case, several embryos that
underwent genome editing were tested for the presence
of intended and unintended genetic modifications.
Then, selected embryos were transferred to a prospective
mother. In this context, we note that genetic testing of
modified embryos may overlook unintended, small ge-
netic modifications that result from the use of insufficiently
programmed nucleases.26 Although the author of the Chi-
nese report claimed that the GGE process ended in
healthy births, it is unlikely that all GGE cases will pro-
ceed without risks to the resultant embryos, fetuses, and
children. As such, no ethics committees are likely to ap-
prove large-scale GGE studies enrolling hundreds or
thousands of couples, even though some authors have
asserted that large studies are needed.28 Indeed, GGE
studies are likely to be limited to small, open-labeled, un-
controlled case series, if performed at all. Although GGE
might attract many prospective parents who have repro-
ductive autonomy, it is likely to remain an experimental
intervention to human reproduction for a long time due to
the limitations of clinical study.
Moral Status of Human Embryos in GGE
It is worth exploring divergent views on prenatal life in
prospective parents who consider GGE. In regard to the
moral considerations regarding the human embryo and
fetus, we can describe the three main outlooks as the
‘‘all,’’ ‘‘none,’’ and ‘‘gradualist’’ positions.29
The ‘‘All’’ position
Those adopting the ‘‘all’’ position hold that human
embryos already possess full human status. For them,
germline genetic modifications, including GGE, are in
themselves acceptable because these unborn ‘‘humans’’
who are suffering from a genetic problem deserve medi-
cal attention.30 At present, however, those holding the
‘‘all’’ position have come to regard such experimental
interventions as unethical, since a relevant addendum
to their position is that there be no risk of adverse events,
no use of reproductive techniques, and few or no wasted
embryos (humans).31 Again, however, they would essen-
tially accept the use of GGE for ensuring the welfare
of unborn ‘‘humans’’ if GGE was perceived as safe, if
it was not considered reproductive medicine, and if it
would contribute to reduce the number of created em-
bryos and, consequently, the number of spare embryos.
The ‘‘None’’ position
Conversely, the ‘‘none’’ position asserts that human
embryos or fetuses have no moral status and therefore
deserve no special moral concern before childbirth. As
such, those holding the ‘‘none’’ position largely accept
germline genetic modifications that can help them to
have genetically related children.
The ‘‘Gradualist’’ position
The ‘‘gradualist’’ position regards human embryos as po-
tential human beings, but not actual humans until birth.
It also considers that human embryos possess a special sta-
tus that deserves a certain degree of respect, which in-
creases along with their development. Similarly to the
‘‘none’’ position, the ‘‘gradualist’’ position may accept
germline genetic modifications for both clinical and re-
search purposes. However, prospective parents are likely
to encounter dilemmas when embryos and fetuses implanted
in the mother are adversely affected. While they may accept
that such embryos and fetuses are morally different from
actual human beings, they may still feel that these entities
should be treated with a higher degree of respect than
genome-edited embryos that have yet to be implanted. In
so doing, it seems unclear whether such affected implanted
embryos and fetuses should be medically treated, as they
were in the SCID gene therapy trial.
Scenarios After GGE and Psychological
Aspects of Parents
To consider scenarios that might arise after GGE, the first
human germline genetic modification is revisited below.
From 1996 to around 2002, an American clinic per-
formed a small study to test a germline mitochondrial
modification technique for intractable female infertility,
wherein the cytoplasm (containing mitochondria) from
a donor egg is transferred into a patient’s eggs (cyto-
plasmic transfer).4 The study helped 13 couples have
17 genetically related children, but also resulted in a mis-
carriage, probably due to a chromosomal abnormality
(Turner syndrome), and one selective fetal reduction from
a twin pregnancy (Turner syndrome). While the pregnant
woman might have been able to support both twins, she
selectively aborted the affected fetus, where the mother’s
reproductive autonomy is generally permitted to take pre-
cedence over the life of the embryo or fetus.32 Of note, it
is virtually impossible to treat affected fetuses fundamen-
tally in cases where many or all of the cells are geneti-
cally abnormal. Likewise, in GGE, while some parents
may have genetically related children, others may choose
to abort adversely affected fetuses.
Pregnant women frequently opt for abortion when pre-
natal testing reveals a genetic abnormality in their fetus.33
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In terms of abortion in cases of germline genetic modifi-
cation, further exploration of the psychological aspects of
the parents is needed due to the potential risks to unborn
children of parents who adopt the ‘‘all position’’ or to
potential children for those who take the ‘‘gradualist po-
sition.’’ In contrast to the cytoplasmic transfer study, the
Chinese GGE case and most GGE basic research intend
to prevent the onset of a disease in offspring prenatally,
despite etiological differences. If prospective parents
who have consented to GGE for that medical purpose,
they are not harboring a vague desire for healthy children
but clearly wish to safeguard genetically related children
against a specific disease. Nonetheless, if issues arise with
the genetic intervention, they may be forced to choose
whether to abort the affected fetuses—namely, whether
to ‘‘kill unborn or potential children.’’ Such conflict
would likely cause substantial grief to such couples.
Safety of GGE for Future Children
From a broader perspective, abortion can play a large role
in integrating GGE into society. Indeed, the U.S. cyto-
plasmic transfer study, in which one affected fetus was
aborted, helped 13 infertile couples to have genetically
related children. However, 1 of the 17 children was sub-
sequently diagnosed with a borderline pervasive develop-
mental disorder, resulting in a regulatory intervention by
the U.S. Food and Drug Administration.34 For genome
editing, a target sequence-binding molecule is designed
primarily using a reference genome. However, the human
genome differs slightly among individuals,35 which may
mislead scientists programming nucleases and result in
unintended genetic modifications. In addition, there is
no perfect prenatal testing. Should GGE become wide-
spread, these limitations of genome editing and prenatal
testing may lead to the birth of some adversely affected
children or the later development of disease in some of
these individuals after they grow. How then should the
safety of experimental GGE be considered?
Once again, we might use as a paradigmatic example
the discussions surrounding mitochondrial donation in
the United Kingdom. In this case, a regulator’s panel con-
cluded in 2013 that ‘‘evidence available at that time did
not suggest that the techniques are unsafe,’’36 which in
part led to the legalization. This suggests that possible
points to consider regarding the safety of GGE include
the presumed probability and seriousness of adverse
events at birth and/or at some future points after preclin-
ical research defined the degree of safety. Is it acceptable
so long as the probability of adverse events after GGE is
far less than one adverse event in 17 children in the case
of cytoplasmic transfer? For some, such a lower probabil-
ity may be acceptable, as most couples have genetically
related healthy children. However, in addition to this
probability, the seriousness of conditions of affected chil-
dren should also be addressed.
On closer examination, unsafe mitochondrial donation
has two different implications. First, the germline mito-
chondrial modification may fail to prevent the inheritance
of serious mitochondrial disease to offspring. This failure
would then result in the birth of children affected by a
serious mitochondrial disease. Second, mitochondrial do-
nation may affect the resultant children in an unexpected
manner, imposing serious conditions other than mito-
chondrial disease upon them. Such conceivable risks to
future children eventually did not halt the legalization
of this procedure in the United Kingdom because those
risks were perceived as acceptably low. Likewise, when
preclinical research further advances, some countries
could justify the clinical use of GGE for medical pur-
poses, probably including the prenatal prevention of
serious disease.
One might view the Chinese researcher’s claim that
twins were born safely via GGE as similar to the first suc-
cessful birth using IVF in 1978, which led to wide use of
technique worldwide. However, small off-target muta-
tions might cause health complications in the children as
they grow. It is therefore crucial to conduct long-term
follow-up of children born via GGE.37 Regarding mito-
chondrial donation, the regulator in the United Kingdom
only requires that reproductive scientists prepare a long-
term follow-up plan,38 suggesting that the long-term
follow-up after GGE will also be left up to scientists
and parents. However, not all the children are likely to
undergo the necessary follow-up. This is not simply be-
cause parents who consented to follow-up may later with-
draw that consent. Of note, in the survey results of families
who joined the cytoplasmic transfer study, only 1 out of 13
couples disclosed the use of the germline genetic mod-
ification to their children, which appears to be lower
than the disclosure rate after the direct reproductive use
of donor eggs.4 This low disclosure rate is probably asso-
ciated with the involvement of ‘‘experimental’’ infusion
of mitochondria derived from donor eggs, which makes
parents hesitate to disclose the fact of conception to
their children. In such a situation, children who are not in-
formed of the fact that they were born using experimental
reproductive medicine may sometimes decline important
hospital visits simply because they do not understand that
their genome was edited, and that medical examinations
are important to offset the potential risks associated with
genome editing. Thus, their health may be threatened in
the future.
The regulator in the United Kingdom requires repro-
ductive scientists to report childbirth with mitochondrial
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disease, birth defects, genetic abnormalities, or other ad-
verse events after mitochondrial donation was performed.38
Aside from issues with long-term safety, consider a situa-
tion in which the use of GGE for preventing serious disease
in future children unexpectedly results in the birth of one
child afflicted with another serious illness. It may be impos-
sible to treat such a child fundamentally, as unsafe genome
editing has unintentionally modified many or all of their
cells. This would be a tragic event for all parents, regardless
of their views on prenatal life, and some parents might even
bring a wrongful birth lawsuit against reproductive scien-
tists.39 However, this lawsuit would likely become a pro-
tracted court case, as it would be unclear whether adverse
events occurred due to the side effects of GGE or to the
genomic instability frequently observed in the early em-
bryos.40 Furthermore, unsafe GGE may later result in fam-
ily discord. In some countries, the affected child could
bring a wrongful life lawsuit against their parents in ad-
dition to reproductive scientists, claiming that she or he
should not have been born.39 However, such actions are un-
likely to be taken by the child because the parents refrain
from disclosing the fact of their conception involving an
experimental genetic intervention. The socially permissive
politics that gave rise to the legality of wrongful birth law-
suits could backfire and diminish the rights of individuals
whose parents attempt to guard preemptively against
wrongful life lawsuits by withholding the facts of their
conception.
Regarding conventional gene therapy, nearly 3,000 tri-
als have been performed worldwide, with a dozen or
more approved therapies.26 Several SGE trials are ongo-
ing at present. With prior review and patient consent,
such clinical efforts are worthwhile because the develop-
ment of SGE as well as gene therapy may satisfy the
needs of current disease sufferers. This is in contrast to
germline genetic modifications. Those who consent to
such germline interventions are prospective parents. Cur-
rent research reports suggest that most of the subjects
would be preimplantation embryos with or without ge-
netic defects that are unborn children for the ‘‘all’’ position
but are morally different from existing humans to those
adopting the ‘‘gradualist’’ or ‘‘none’’ position. For prospec-
tive parents with reproductive autonomy, GGE can be
viewed as wish-fulfilling medicine.41 Namely, GGE can
help such parents create genetically related children with
or without a specific trait. In contrast, some argue that germ-
line genetic modification has few compelling needs and lit-
tle social value.21,22 In addition, unintended off-target
mutations may adversely affect germline cells, potentially
ruining the welfare of the resultant children, which conflicts
with the ideals laid out in the NCB report. If countries judge
that the potential harms to future children as well as the rel-
ative paucity of compelling needs or social value outweigh
parental wishes for having genetically related children, they
will maintain or prohibit GGE. On the other hand, in the
United Kingdom, mitochondrial donation is legal for
prospective parents pursuing genetically related healthy
children. Therefore, the acceptability of GGE largely de-
pends on its safety, as well as the degree of respect for pa-
rental reproductive autonomy. Is the risk of unintended
victims of GGE an acceptable risk for such parents? At
present, it is doubtful whether prospective parents suffi-
ciently perceive the safety implications of GGE.
Conclusion
Given that GGE is more likely to spread than older germ-
line genetic modifications, and that GGE carries a real
risk of adversely affecting children with human rights
in an irretrievable manner, it is vital for prospective par-
ents with reproductive autonomy, as well as scientists and
policy makers, to perceive the safety implications of ex-
perimental GGE for the genetically related future chil-
dren. It also important to open a social debate on the
necessity of disclosing the use of GGE to the Chinese
twins and individuals whose birth involved the technique
if we wish to guarantee their fundamental rights.
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